Creatine monohydrate

Drug Profile

Creatine monohydrate

Alternative Names: AL-02; AL-05; ALS-02; ALS-05; ALS-08/celecoxib; ALS-08/minocycline; CMT-02; CTD-02; CTD-09; DMD-02; HD-02; NEOtine; PD-01; PD-02; PD-04; PD-06; PURE ENERGY

Latest Information Update: 03 Jun 2010

Price : $50

At a glance

  • Originator Avicena Group
  • Class Amino acids; Guanidines; Neuroprotectants; Small molecules
  • Mechanism of Action Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease; Amyotrophic lateral sclerosis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Huntington's disease; Metabolic disorders; Neuromuscular disorders; Parkinson's disease

Most Recent Events

  • 03 Jun 2010 No development reported - Phase-I for Neuromuscular disorders in USA (PO)
  • 03 Jun 2010 No development reported - Phase-II for Huntington's disease in USA (PO)
  • 03 Jun 2010 No development reported - Phase-III for Amyotrophic lateral sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top